(Q38041660)

English

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.

scientific article published on 03 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

0 references

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

K S Boye

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

L Timlin

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

J F Clark

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

J H Best

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

3 October 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

213-223

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Performing meta-analysis with incomplete statistical information in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Checking consistency in mixed treatment comparison meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Bayesian measures of model complexity and fit

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Investigating underlying risk as a source of heterogeneity in meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12007

21 January 2018

Identifiers

10.1111/DOM.12007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958381%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38041660&oldid=1644873000"